Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the
recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six
weeks and possibly up to 12 weeks depending on response.